Science Daily reports on a recent publication by researchers at Stanford, Mayo Clinic, and Atomwise.
Atomwise could receive up to US$1.5 billion to develop first in-class and best in-class small molecules through partnership with China’s leading biopharmaceutical company, Hansoh Pharma.
Mark Terry of BioSpace reports on Atomwise’s three new joint ventures.
Atomwise and Atropos Therapeutics form a joint venture to discover and develop anticancer agents using senescence assay and AI technologies.
Connor Hale at FierceBiotech writes about Atomwise’s new joint ventures with SEngine Precision Medicine and OncoStatyx.
Noah Miller of Newsweek interviews Abraham Heifets, Atomwise CEO, about his Moonshot.